Nyrada, Inc. · ASX:NYR
Nyrada — ASX SMIDCaps Conference 2026
12 slides from Nyrada's conference presentation, Mar 25, 2026
Slide 1: ASX SMIDCaps Conference
ASX SMIDCaps Conference James Bonnar Managing Director and CEO 25 March 2026 | Sydney, Australia ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 3: Heart Attack (STEMI)
Heart Attack (STEMI) A critical blockage requiring immediate treatment • Heart attack caused by restricted blood flow → myocardial ischemia • STEMI (ST-elevation myocardial infarction) is a complete blockage • Globally, ~7 million acute coronary syndrome (ACS) cases annually, ~30% are STEMI* • Requi
Slide 4: Standard Treatment and Reperfusion Injury
Standard Treatment and Reperfusion Injury Restoring blood flow following heart attack saves lives but causes additional injury • PCI (balloon angioplasty plus stenting): – First angioplasty procedure in 1977 – Standard of care for STEMI by early 2000s – Global PCI procedures: ~4M per year* • Reperfu
Slide 5: Clinical Consequence of Reperfusion Injury
Clinical Consequence of Reperfusion Injury Increased heart damage worsens outcomes, drives heart failure and mortality Clinical studies* show that reducing heart muscle damage lowers risk of heart failure hospitalisation • 5% reduction in infarct size → ~17% lower risk of heart failure hospitalisati
Slide 6: Xolatryp - Cardioprotective Therapy
Xolatryp® - Cardioprotective Therapy Targeting TRPC channels to reduce heart damage following heart attack › Lead clinical candidate – Xolatryp® › Targets TRPC channels involved in the biological pathways driving reperfusion injury › Strong efficacy in reducing injury demonstrated in multiple precli
Slide 7: Preclinical Evidence of Cardioprotection
Preclinical Evidence of Cardioprotection Two studies showed Xolatryp markedly limits cardiovascular damage from myocardial ischemia-reperfusion injury A 24-hr dosing study showed: Cardioprotection Reperfusion + drug Reperfusion + vehicle • 86% smaller infarct (42% in 3-hr dosing study) • Decreases i
Slide 8: Phase IIa Clinical Trial
Phase IIa Clinical Trial Xolatryp to be assessed for safety and preliminary efficacy in patients with STEMI who undergo primary Percutaneous Coronary Intervention (PCI) Primary End Point – Safety and tolerability Further End Points – Preliminary efficacy: • Cardiac injury size • Biomarkers, includin
Slide 9: Large Market Opportunity
Large Market Opportunity Even modest penetration in the PCI population represents a multi-billion-dollar opportunity • Treatment of reperfusion injury is the last frontier in acute heart attack management • Xolatryp – novel therapy targeting unmet clinical need ‒ First therapy targeting reperfusion
Slide 10: Corporate & Investment Highlights
Corporate & Investment Highlights › Nyrada – the company › Pioneering TRPC channel inhibitor therapies to treat a range of medical conditions › AU$7.12 million cash position at end December 2025 › AU$2.16 million R&D rebated expected › AU$0.51 million option exercise capital 3QFY2026 YTD › Xolatryp
Slide 11: Key Links
Key Links Program • PROTECT-MI website – https://www.protect-mi.com • Phase IIa factsheet – https://bit.ly/4bcDlKj • Phase I results – https://bit.ly/3Nt0GzH • GLP study results – https://bit.ly/4d8VYkX • Preclinical cardioprotection study 1a – https://bit.ly/4sigwMZ • Preclinical cardioprotection s
Slide 12: Nyrada contact details
@nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 12